ESMO 2014: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)